295 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
LGND Ligand Pharmaceuticals Incorporated $253.56 $5.35B N/A
Article Searches
Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $108,200 of Shares http://www.gurufocus.com/news/888018/ligand-pharmaceuticals-inc-lgnd-ceo-john-l-higgins-bought-108200-of-shares May 31, 2019 - Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $108,200 of Shares, Stocks: LGND, release date:May 31, 2019
Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $283,750 of Shares http://www.gurufocus.com/news/877972/ligand-pharmaceuticals-inc-lgnd-ceo-john-l-higgins-bought-283750-of-shares May 14, 2019 - Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $283,750 of Shares, Stocks: LGND, release date:May 14, 2019
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates http://www.zacks.com/stock/news/411554/amag-q1-loss-wider-than-expected-revenues-lag-estimates?cid=CS-ZC-FT-411554 May 09, 2019 - AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss http://www.zacks.com/stock/news/410473/mylans-myl-q1-earnings-beat-estimates-revenues-miss?cid=CS-ZC-FT-410473 May 07, 2019 - Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.
Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4259419-ligand-pharmaceuticals-lgnd-ceo-john-higgins-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare May 02, 2019 - Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Q1 2019 Earnings Conference Call May 2, 2019 4:30 PM ET Company Participants Todd Pettingill – Investor Relations John Higgins – Chief Executive Officer Matt
Ligand Pharmaceuticals Incorporated (LGND) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/05/02/ligand-pharmaceuticals-incorporated-lgnd-q1-2019-e.aspx?source=iedfolrf0000001 May 02, 2019 - LGND earnings call for the period ending March 30, 2019.
Ligand Pharmaceuticals (LGND) Reports Next Week: Wall Street Expects Earnings Growth http://www.zacks.com/stock/news/399492/ligand-pharmaceuticals-lgnd-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-399492 Apr 25, 2019 - Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Sage Therapeutics a Good Stock to Buy Now? https://www.fool.com/investing/2019/03/20/is-sage-therapeutics-a-good-stock-to-buy-now.aspx?source=iedfolrf0000001 Mar 20, 2019 - Earning the first FDA approval for treating postpartum depression is a big step, but it's hardly an express ticket to profit town.
Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $285,725 of Shares http://www.gurufocus.com/news/833330/ligand-pharmaceuticals-inc-lgnd-ceo-john-l-higgins-bought-285725-of-shares Mar 15, 2019 - Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $285,725 of Shares, Stocks: LGND, release date:Mar 15, 2019
LGND vs. ILMN: Which Stock Should Value Investors Buy Now? http://www.zacks.com/stock/news/359734/lgnd-vs-ilmn-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-359734 Mar 15, 2019 - LGND vs. ILMN: Which Stock Is the Better Value Option?

Pages: 123456...30

Page 1>